{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:04:23Z","timestamp":1790327063986,"version":"4.1.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100015401","name":"Key Research and Development Projects of Shaanxi Province","doi-asserted-by":"publisher","award":["2025SF-YBXM-356"],"award-info":[{"award-number":["2025SF-YBXM-356"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015401","name":"Key Research and Development Projects of Shaanxi Province","doi-asserted-by":"publisher","award":["2026SF-YBXM-276"],"award-info":[{"award-number":["2026SF-YBXM-276"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Huadong Medicine Joint Funds of the Zhejiang Provincial Natural Science Foundation of China","award":["LHDMD23H300002"],"award-info":[{"award-number":["LHDMD23H300002"]}],"id":[{"id":"https:\/\/ror.org\/04aqat463","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Oncol."],"DOI":"10.1007\/s13402-026-01282-7","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T09:35:04Z","timestamp":1787650504000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["OTUD1-mediated deubiquitination stabilizes SLC7A11 to suppress ferroptosis in hepatocellular carcinoma"],"prefix":"10.1007","volume":"49","author":[{"given":"Runtian","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanye","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6002-036X","authenticated-orcid":false,"given":"Qingguang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0032-1459","authenticated-orcid":false,"given":"Kangsheng","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"issue":"1","key":"1282_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"J.M. Llovet, R.K. Kelley, A. Villanueva, A.G. Singal, E. Pikarsky, S. Roayaie, R. Lencioni, K. Koike, J. Zucman-Rossi, R.S. Finn, Hepatocellular carcinoma. Nat. Rev. Dis. Primers. 7(1), 6 (2021)","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"15","key":"1282_CR2","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"A. Villanueva, Hepatocellular Carcinoma. N Engl. J. Med. 380(15), 1450\u20131462 (2019)","journal-title":"N Engl. J. Med."},{"issue":"3","key":"1282_CR3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","volume":"19","author":"JM Llovet","year":"2022","unstructured":"J.M. Llovet, F. Castet, M. Heikenwalder, M.K. Maini, V. Mazzaferro, D.J. Pinato, E. Pikarsky, A.X. Zhu, R.S. Finn, Immunotherapies for hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 19(3), 151\u2013172 (2022)","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1282_CR4","doi-asserted-by":"crossref","unstructured":"A.D. Ladd, S. Duarte, I. Sahin, A. Zarrinpar, Mechanisms of drug resistance in HCC. Hepatology. 79(4), 926\u2013940 (2024)","DOI":"10.1097\/HEP.0000000000000237"},{"issue":"8","key":"1282_CR5","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1111\/liv.15953","volume":"44","author":"Y Qin","year":"2024","unstructured":"Y. Qin, S. Han, Y. Yu, D. Qi, M. Ran, M. Yang, Y. Liu, Y. Li, L. Lu, Y. Liu et al., Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy. Liver Int. 44(8), 1808\u20131831 (2024)","journal-title":"Liver Int."},{"issue":"12","key":"1282_CR6","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1002\/mc.23625","volume":"62","author":"A Buttell","year":"2023","unstructured":"A. Buttell, W. Qiu, The action and resistance mechanisms of Lenvatinib in liver cancer. Mol. Carcinog. 62(12), 1918\u20131934 (2023)","journal-title":"Mol. Carcinog."},{"issue":"5","key":"1282_CR7","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"S.J. Dixon, K.M. Lemberg, M.R. Lamprecht, R. Skouta, E.M. Zaitsev, C.E. Gleason, D.N. Patel, A.J. Bauer, A.M. Cantley, W.S. Yang et al., Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 149(5), 1060\u20131072 (2012)","journal-title":"Cell"},{"issue":"4","key":"1282_CR8","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"X. Jiang, B.R. Stockwell, M. Conrad, Ferroptosis: mechanisms, biology and role in disease. Nat. Rev. Mol. Cell. Biol. 22(4), 266\u2013282 (2021)","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"issue":"3","key":"1282_CR9","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1097\/HEP.0000000000000390","volume":"80","author":"D Tang","year":"2024","unstructured":"D. Tang, G. Kroemer, R. Kang, Ferroptosis in hepatocellular carcinoma: from bench to bedside. Hepatology. 80(3), 721\u2013739 (2024)","journal-title":"Hepatology"},{"issue":"9","key":"1282_CR10","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.7150\/ijbs.96014","volume":"20","author":"X Zhu","year":"2024","unstructured":"X. Zhu, X. Sha, Y. Zang, Q. Ren, S. Zhang, D. Ma, L. Wang, J. Yao, X. Zhou, L. Yu et al., Current Progress of Ferroptosis Study in Hepatocellular Carcinoma. Int. J. Biol. Sci. 20(9), 3621\u20133637 (2024)","journal-title":"Int. J. Biol. Sci."},{"issue":"7","key":"1282_CR11","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41568-022-00459-0","volume":"22","author":"G Lei","year":"2022","unstructured":"G. Lei, L. Zhuang, B. Gan, Targeting ferroptosis as a vulnerability in cancer. Nat. Rev. Cancer. 22(7), 381\u2013396 (2022)","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"1282_CR12","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41416-022-01998-x","volume":"128","author":"A Ajoolabady","year":"2023","unstructured":"A. Ajoolabady, D. Tang, G. Kroemer, J. Ren, Ferroptosis in hepatocellular carcinoma: mechanisms and targeted therapy. Br. J. Cancer. 128(2), 190\u2013205 (2023)","journal-title":"Br. J. Cancer"},{"issue":"5","key":"1282_CR13","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.7150\/ijbs.107195","volume":"21","author":"R Chen","year":"2025","unstructured":"R. Chen, X. Hu, Y. Huang, Y. Jiang, G. Chen, Q. Shan, X. Xu, S. Zheng, Regulated Cell Death in Lenvatinib Resistance of Hepatocellular Carcinoma: from Molecular Mechanisms to Therapeutic Strategies. Int. J. Biol. Sci. 21(5), 2012\u20132026 (2025)","journal-title":"Int. J. Biol. Sci."},{"issue":"7","key":"1282_CR14","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1111\/cas.15378","volume":"113","author":"N Iseda","year":"2022","unstructured":"N. Iseda, S. Itoh, K. Toshida, T. Tomiyama, A. Morinaga, M. Shimokawa, T. Shimagaki, H. Wang, T. Kurihara, T. Toshima et al., Ferroptosis is induced by lenvatinib through fibroblast growth factor receptor-4 inhibition in hepatocellular carcinoma. Cancer Sci. 113(7), 2272\u20132287 (2022)","journal-title":"Cancer Sci."},{"key":"1282_CR15","doi-asserted-by":"publisher","first-page":"101224","DOI":"10.1016\/j.drup.2025.101224","volume":"81","author":"Z Zhang","year":"2025","unstructured":"Z. Zhang, Q. Zhou, Z. Li, F. Huang, K. Mo, C. Shen, X. Niu, B. Hou, C. Zhang, S. Huang, DTX2 attenuates Lenvatinib-induced ferroptosis by suppressing docosahexaenoic acid biosynthesis through HSD17B4-dependent peroxisomal \u03b2-oxidation in hepatocellular carcinoma. Drug Resist. Updat. 81, 101224 (2025)","journal-title":"Drug Resist. Updat"},{"issue":"27","key":"1282_CR16","doi-asserted-by":"publisher","first-page":"e2501730","DOI":"10.1002\/advs.202501730","volume":"12","author":"J Zhou","year":"2025","unstructured":"J. Zhou, M. Gao, S. Zhang, W.W. Guo, W. He, M. Zhang, X. Chen, C. Dongzhi, X. Li, Y. Yuan et al., PP1A Modulates the Efficacy of Lenvatinib Plus ICIs Therapy by Inhibiting Ferroptosis in Hepatocellular Carcinoma. Adv. Sci. (Weinh). 12(27), e2501730 (2025)","journal-title":"Adv. Sci. (Weinh)"},{"key":"1282_CR17","doi-asserted-by":"publisher","first-page":"115656","DOI":"10.1016\/j.intimp.2025.115656","volume":"167","author":"S Liang","year":"2025","unstructured":"S. Liang, G. Huang, M. Fu, Y. Shi, X. Tu, W. Lin, J. Tian, X. Zhai, B. Cheng, Arsenic trioxide enhances the inhibitory effect of lenvatinib on hepatocellular carcinoma through HMOX1-mediated ferroptosis. Int. Immunopharmacol. 167, 115656 (2025)","journal-title":"Int. Immunopharmacol."},{"issue":"7","key":"1282_CR18","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.1007\/s11010-025-05218-x","volume":"480","author":"Z Chen","year":"2025","unstructured":"Z. Chen, L. Ou, L. Ma, SOX11 exacerbates ferroptosis to reduce lenvatinib resistance in liver cancer cells by promoting ubiquitination degradation of SREBF1 through upregulating UBE3A. Mol. Cell. Biochem. 480(7), 4119\u20134134 (2025)","journal-title":"Mol. Cell. Biochem."},{"issue":"14","key":"1282_CR19","doi-asserted-by":"publisher","first-page":"5475","DOI":"10.7150\/ijbs.73790","volume":"18","author":"Y Meng","year":"2022","unstructured":"Y. Meng, H. Sun, Y. Li, S. Zhao, J. Su, F. Zeng, G. Deng, X. Chen, Targeting Ferroptosis by Ubiquitin System Enzymes: A Potential Therapeutic Strategy in Cancer. Int. J. Biol. Sci. 18(14), 5475\u20135488 (2022)","journal-title":"Int. J. Biol. Sci."},{"key":"1282_CR20","doi-asserted-by":"publisher","first-page":"1383203","DOI":"10.3389\/fphar.2024.1383203","volume":"15","author":"MAU Din","year":"2024","unstructured":"M.A.U. Din, Y. Lin, N. Wang, B. Wang, F. Mao, Ferroptosis and the ubiquitin-proteasome system: exploring treatment targets in cancer. Front. Pharmacol. 15, 1383203 (2024)","journal-title":"Front. Pharmacol."},{"issue":"1","key":"1282_CR21","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12943-024-02046-3","volume":"23","author":"F Liu","year":"2024","unstructured":"F. Liu, J. Chen, K. Li, H. Li, Y. Zhu, Y. Zhai, B. Lu, Y. Fan, Z. Liu, X. Chen et al., Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches. Mol. Cancer. 23(1), 148 (2024)","journal-title":"Mol. Cancer"},{"issue":"3","key":"1282_CR22","doi-asserted-by":"publisher","first-page":"101077","DOI":"10.1016\/j.jbc.2021.101077","volume":"297","author":"NA Snyder","year":"2021","unstructured":"N.A. Snyder, G.M. Silva, Deubiquitinating enzymes (DUBs): Regulation, homeostasis, and oxidative stress response. J. Biol. Chem. 297(3), 101077 (2021)","journal-title":"J. Biol. Chem."},{"issue":"2","key":"1282_CR23","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41594-024-01221-w","volume":"31","author":"S Rahman","year":"2024","unstructured":"S. Rahman, C. Wolberger, Breaking the K48-chain: linking ubiquitin beyond protein degradation. Nat. Struct. Mol. Biol. 31(2), 216\u2013218 (2024)","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"36","key":"1282_CR24","doi-asserted-by":"publisher","first-page":"e2303807","DOI":"10.1002\/advs.202303807","volume":"10","author":"J Ren","year":"2023","unstructured":"J. Ren, P. Yu, S. Liu, R. Li, X. Niu, Y. Chen, Z. Zhang, F. Zhou, L. Zhang, Deubiquitylating Enzymes in Cancer and Immunity. Adv. Sci. (Weinh). 10(36), e2303807 (2023)","journal-title":"Adv. Sci. (Weinh)"},{"issue":"4","key":"1282_CR25","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1080\/15548627.2019.1656957","volume":"16","author":"K Niu","year":"2020","unstructured":"K. Niu, H. Fang, Z. Chen, Y. Zhu, Q. Tan, D. Wei, Y. Li, A.S. Balajee, Y. Zhao, USP33 deubiquitinates PRKN\/parkin and antagonizes its role in mitophagy. Autophagy. 16(4), 724\u2013734 (2020)","journal-title":"Autophagy"},{"key":"1282_CR26","doi-asserted-by":"publisher","first-page":"103287","DOI":"10.1016\/j.redox.2024.103287","volume":"75","author":"Q Zhang","year":"2024","unstructured":"Q. Zhang, Z. Chen, J. Li, K. Huang, Z. Ding, B. Chen, T. Ren, P. Xu, G. Wang, H. Zhang et al., The deubiquitinase OTUD1 stabilizes NRF2 to alleviate hepatic ischemia\/reperfusion injury. Redox Biol. 75, 103287 (2024)","journal-title":"Redox Biol."},{"key":"1282_CR27","doi-asserted-by":"publisher","first-page":"114985","DOI":"10.1016\/j.intimp.2025.114985","volume":"160","author":"Q Wang","year":"2025","unstructured":"Q. Wang, H. Liu, M. Yuan, Y. Wang, J. Qin, X. Chen, Z. Lei, X. Song, X. Wu, OTUD1 inhibits macrophage ferroptosis via regulation of AMPK and GSK3\u03b2\/\u03b2-catenin signaling pathways exerting protective effects in sepsis-induced acute lung injury. Int. Immunopharmacol. 160, 114985 (2025)","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"1282_CR28","doi-asserted-by":"publisher","first-page":"e51162","DOI":"10.15252\/embr.202051162","volume":"22","author":"J Song","year":"2021","unstructured":"J. Song, T. Liu, Y. Yin, W. Zhao, Z. Lin, Y. Yin, D. Lu, F. You, The deubiquitinase OTUD1 enhances iron transport and potentiates host antitumor immunity. EMBO Rep. 22(2), e51162 (2021)","journal-title":"EMBO Rep."},{"issue":"1","key":"1282_CR29","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41420-024-01863-1","volume":"10","author":"Y Jiang","year":"2024","unstructured":"Y. Jiang, Y. Yu, Z. Pan, C. Glandorff, M. Sun, Ferroptosis: a new hunter of hepatocellular carcinoma. Cell. Death Discov. 10(1), 136 (2024)","journal-title":"Cell. Death Discov"},{"issue":"1","key":"1282_CR30","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13045-024-01599-6","volume":"17","author":"J Wang","year":"2024","unstructured":"J. Wang, M. Xiu, J. Wang, Y. Gao, Y. Li, METTL16-SENP3-LTF axis confers ferroptosis resistance and facilitates tumorigenesis in hepatocellular carcinoma. J. Hematol. Oncol. 17(1), 78 (2024)","journal-title":"J. Hematol. Oncol."},{"issue":"29","key":"1282_CR31","doi-asserted-by":"publisher","first-page":"e2301928","DOI":"10.1002\/advs.202301928","volume":"10","author":"Y Zheng","year":"2023","unstructured":"Y. Zheng, Y. Wang, Z. Lu, J. Wan, L. Jiang, D. Song, C. Wei, C. Gao, G. Shi, J. Zhou et al., PGAM1 Inhibition Promotes HCC Ferroptosis and Synergizes with Anti-PD-1 Immunotherapy. Adv. Sci. (Weinh). 10(29), e2301928 (2023)","journal-title":"Adv. Sci. (Weinh)"},{"issue":"1","key":"1282_CR32","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13046-024-03047-2","volume":"43","author":"Y Yuan","year":"2024","unstructured":"Y. Yuan, J. Xu, Q. Jiang, C. Yang, N. Wang, X. Liu, H.L. Piao, S. Lu, X. Zhang, L. Han et al., Ficolin 3 promotes ferroptosis in HCC by downregulating IR\/SREBP axis-mediated MUFA synthesis. J. Exp. Clin. Cancer Res. 43(1), 133 (2024)","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"1282_CR33","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s13046-023-02865-0","volume":"42","author":"J Huang","year":"2023","unstructured":"J. Huang, H. Pan, J. Sun, J. Wu, Q. Xuan, J. Wang, S. Ke, S. Lu, Z. Li, Z. Feng et al., TMEM147 aggravates the progression of HCC by modulating cholesterol homeostasis, suppressing ferroptosis, and promoting the M2 polarization of tumor-associated macrophages. J. Exp. Clin. Cancer Res. 42(1), 286 (2023)","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1282_CR34","doi-asserted-by":"publisher","first-page":"156304","DOI":"10.1016\/j.metabol.2025.156304","volume":"170","author":"GQ Pan","year":"2025","unstructured":"G.Q. Pan, Y.C. Yan, R.Z. Li, C. Xiong, S.P. Zhang, Y. Qu, R. Dong, Y. Zhou, T.S. Zhang, Z.Q. Chen et al., Targeting SAMD1 enhances the effect of anti-PD-1 plus lenvatinib therapy in hepatocellular carcinoma by increasing ferroptosis sensitivity and immune response. Metabolism. 170, 156304 (2025)","journal-title":"Metabolism"},{"issue":"33","key":"1282_CR35","doi-asserted-by":"publisher","first-page":"e2302953","DOI":"10.1002\/advs.202302953","volume":"10","author":"J Tang","year":"2023","unstructured":"J. Tang, G. Long, K. Hu, D. Xiao, S. Liu, L. Xiao, L. Zhou, Y. Tao, Targeting USP8 Inhibits O-GlcNAcylation of SLC7A11 to Promote Ferroptosis of Hepatocellular Carcinoma via Stabilization of OGT. Adv. Sci. (Weinh). 10(33), e2302953 (2023)","journal-title":"Adv. Sci. (Weinh)"},{"key":"1282_CR36","doi-asserted-by":"crossref","unstructured":"B. Yan, J. Guo, Z. Wang, J. Ning, H. Wang, L. Shu, K. Hu, L. Chen, Y. Shi, L. Zhang et al., The ubiquitin-specific protease 5 mediated deubiquitination of LSH links metabolic regulation of ferroptosis to hepatocellular carcinoma progression. MedComm (2020). 4(4), e337 (2023)","DOI":"10.1002\/mco2.337"},{"issue":"6","key":"1282_CR37","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41419-023-05747-7","volume":"14","author":"J Tang","year":"2023","unstructured":"J. Tang, G. Long, L. Xiao, L. Zhou, USP8 positively regulates hepatocellular carcinoma tumorigenesis and confers ferroptosis resistance through \u03b2-catenin stabilization. Cell. Death Dis. 14(6), 360 (2023)","journal-title":"Cell. Death Dis."},{"issue":"1","key":"1282_CR38","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41419-025-07807-6","volume":"16","author":"X Yue","year":"2025","unstructured":"X. Yue, Z. Xiang, Y. Yi, X. Wang, W. Zhou, W. Wu, W. Qin, Y. Zhao, X. Bu, Z. Peng, Targeting the TRIM14\/USP14 axis enhances radiotherapy efficacy by inducing GPX4 degradation and disrupting ferroptotic defense in HCC. Cell. Death Dis. 16(1), 481 (2025)","journal-title":"Cell. Death Dis."},{"issue":"8","key":"1282_CR39","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s13238-020-00789-5","volume":"12","author":"P Koppula","year":"2021","unstructured":"P. Koppula, L. Zhuang, B. Gan, Cystine transporter SLC7A11\/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 12(8), 599\u2013620 (2021)","journal-title":"Protein Cell."},{"issue":"1","key":"1282_CR40","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40880-018-0288-x","volume":"38","author":"P Koppula","year":"2018","unstructured":"P. Koppula, Y. Zhang, L. Zhuang, B. Gan, Amino acid transporter SLC7A11\/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun. (Lond). 38(1), 12 (2018)","journal-title":"Cancer Commun. (Lond)"},{"issue":"10","key":"1282_CR41","first-page":"3106","volume":"10","author":"W Lin","year":"2020","unstructured":"W. Lin, C. Wang, G. Liu, C. Bi, X. Wang, Q. Zhou, H. Jin, SLC7A11\/xCT in cancer: biological functions and therapeutic implications. Am. J. Cancer Res. 10(10), 3106\u20133126 (2020)","journal-title":"Am. J. Cancer Res."},{"key":"1282_CR42","doi-asserted-by":"crossref","unstructured":"J. Lee, J.L. Roh, SLC7A11 as a gateway of metabolic perturbation and ferroptosis vulnerability in cancer. Antioxidants (Basel). 11(12), (2022)","DOI":"10.3390\/antiox11122444"},{"issue":"1","key":"1282_CR43","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.1038\/s41467-023-39401-9","volume":"14","author":"Y Yan","year":"2023","unstructured":"Y. Yan, H. Teng, Q. Hang, L. Kondiparthi, G. Lei, A. Horbath, X. Liu, C. Mao, S. Wu, L. Zhuang et al., SLC7A11 expression level dictates differential responses to oxidative stress in cancer cells. Nat. Commun. 14(1), 3673 (2023)","journal-title":"Nat. Commun."},{"issue":"1","key":"1282_CR44","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41418-023-01239-5","volume":"31","author":"Z Wang","year":"2024","unstructured":"Z. Wang, N. Shen, Z. Wang, L. Yu, S. Yang, Y. Wang, Y. Liu, G. Han, Q. Zhang, TRIM3 facilitates ferroptosis in non-small cell lung cancer through promoting SLC7A11\/xCT K11-linked ubiquitination and degradation. Cell. Death Differ. 31(1), 53\u201364 (2024)","journal-title":"Cell. Death Differ."},{"key":"1282_CR45","doi-asserted-by":"crossref","unstructured":"W. Zhang, Y. Sun, L. Bai, L. Zhi, Y. Yang, Q. Zhao, C. Chen, Y. Qi, W. Gao, W. He et al., RBMS1 regulates lung cancer ferroptosis through translational control of SLC7A11. J. Clin. Invest. 131(22), (2021)","DOI":"10.1172\/JCI152067"},{"issue":"1","key":"1282_CR46","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s13046-021-02012-7","volume":"40","author":"J Yang","year":"2021","unstructured":"J. Yang, Y. Zhou, S. Xie, J. Wang, Z. Li, L. Chen, M. Mao, C. Chen, A. Huang, Y. Chen et al., Metformin induces Ferroptosis by inhibiting UFMylation of SLC7A11 in breast cancer. J. Exp. Clin. Cancer Res. 40(1), 206 (2021)","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"14","key":"1282_CR47","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.7150\/ijbs.74546","volume":"18","author":"L Shen","year":"2022","unstructured":"L. Shen, J. Zhang, Z. Zheng, F. Yang, S. Liu, Y. Wu, Y. Chen, T. Xu, S. Mao, Y. Yan et al., PHGDH Inhibits Ferroptosis and Promotes Malignant Progression by Upregulating SLC7A11 in Bladder Cancer. Int. J. Biol. Sci. 18(14), 5459\u20135474 (2022)","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"1282_CR48","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s12967-023-04136-0","volume":"21","author":"X Zhang","year":"2023","unstructured":"X. Zhang, X. Zheng, X. Ying, W. Xie, Y. Yin, X. Wang, CEBPG suppresses ferroptosis through transcriptional control of SLC7A11 in ovarian cancer. J. Transl Med. 21(1), 334 (2023)","journal-title":"J. Transl Med."},{"issue":"22","key":"1282_CR49","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1038\/s41388-024-02996-4","volume":"43","author":"N Cao","year":"2024","unstructured":"N. Cao, F. Zhang, J. Yin, J. Zhang, X. Bian, G. Zheng, N. Li, Y. Lin, L. Luo, LPCAT2 inhibits colorectal cancer progression via the PRMT1\/SLC7A11 axis. Oncogene. 43(22), 1714\u20131725 (2024)","journal-title":"Oncogene"},{"issue":"6","key":"1282_CR50","doi-asserted-by":"publisher","first-page":"e248","DOI":"10.1002\/imt2.248","volume":"3","author":"Y Jin","year":"2024","unstructured":"Y. Jin, S. Cai, Y. Zhou, D. Guo, Y. Zeng, W. Xu, Y. Sun, Y. Shi, Z. Xu, Z. Liu et al., Targeting SLC7A11\/xCT improves radiofrequency ablation efficacy of HCC by dendritic cells mediated anti-tumor immune response. Imeta. 3(6), e248 (2024)","journal-title":"Imeta"},{"issue":"2","key":"1282_CR51","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jhep.2023.03.016","volume":"79","author":"F He","year":"2023","unstructured":"F. He, P. Zhang, J. Liu, R. Wang, R.J. Kaufman, B.C. Yaden, M. Karin, ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis. J. Hepatol. 79(2), 362\u2013377 (2023)","journal-title":"J. Hepatol."},{"key":"1282_CR52","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jare.2024.08.021","volume":"73","author":"S Wang","year":"2025","unstructured":"S. Wang, X. Yuan, Z. Yang, X. Zhang, Z. Xu, L. Yang, X. Yang, W. Zhou, W. Liu, Matrix stiffness-dependent PD-L2 deficiency improves SMYD3\/xCT-mediated ferroptosis and the efficacy of anti-PD-1 in HCC. J. Adv. Res. 73, 265\u2013282 (2025)","journal-title":"J. Adv. Res."},{"issue":"1","key":"1282_CR53","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12943-024-02224-3","volume":"24","author":"Y Zhang","year":"2025","unstructured":"Y. Zhang, R. Yao, M. Li, C. Fang, K. Feng, X. Chen, J. Wang, R. Luo, H. Shi, X. Chen et al., CircTTC13 promotes sorafenib resistance in hepatocellular carcinoma through the inhibition of ferroptosis by targeting the miR-513a-5p\/SLC7A11 axis. Mol. Cancer. 24(1), 32 (2025)","journal-title":"Mol. Cancer"},{"issue":"1","key":"1282_CR54","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41419-024-07317-x","volume":"16","author":"C Zhang","year":"2025","unstructured":"C. Zhang, T. Yang, H. Chen, X. Ding, H. Chen, Z. Liang, Y. Zhao, S. Ma, X. Liu, METTL3 inhibition promotes radiosensitivity in hepatocellular carcinoma through regulation of SLC7A11 expression. Cell. Death Dis. 16(1), 9 (2025)","journal-title":"Cell. Death Dis."},{"key":"1282_CR55","doi-asserted-by":"publisher","first-page":"101181","DOI":"10.1016\/j.drup.2024.101181","volume":"78","author":"CJ Shi","year":"2025","unstructured":"C.J. Shi, F.X. Pang, Y.H. Lei, L.Q. Deng, F.Z. Pan, Z.Q. Liang, T. Xie, X.L. Wu, Y.Y. Wang, Y.F. Xian et al., 5-methylcytosine methylation of MALAT1 promotes resistance to sorafenib in hepatocellular carcinoma through ELAVL1\/SLC7A11-mediated ferroptosis. Drug Resist. Updat. 78, 101181 (2025)","journal-title":"Drug Resist. Updat"},{"issue":"2","key":"1282_CR56","doi-asserted-by":"publisher","first-page":"e2203973","DOI":"10.1002\/advs.202203973","volume":"10","author":"B Tang","year":"2023","unstructured":"B. Tang, J. Zhu, Y. Wang, W. Chen, S. Fang, W. Mao, Z. Xu, Y. Yang, Q. Weng, Z. Zhao et al., Targeted xCT-mediated Ferroptosis and Protumoral Polarization of Macrophages Is Effective against HCC and Enhances the Efficacy of the Anti-PD-1\/L1 Response. Adv. Sci. (Weinh). 10(2), e2203973 (2023)","journal-title":"Adv. Sci. (Weinh)"},{"issue":"10","key":"1282_CR57","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/s41418-024-01324-3","volume":"31","author":"J Chu","year":"2024","unstructured":"J. Chu, J. Jiang, X. Fan, J. Liu, K. Gao, Y. Jiang, M. Li, W. Xi, L. Zhang, K. Bian et al., A novel MYC-ZNF706-SLC7A11 regulatory circuit contributes to cancer progression and redox balance in human hepatocellular carcinoma. Cell. Death Differ. 31(10), 1333\u20131348 (2024)","journal-title":"Cell. Death Differ."},{"issue":"8","key":"1282_CR58","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1158\/0008-5472.CAN-18-3037","volume":"79","author":"T Liu","year":"2019","unstructured":"T. Liu, L. Jiang, O. Tavana, W. Gu, The Deubiquitylase OTUB1 Mediates Ferroptosis via Stabilization of SLC7A11. Cancer Res. 79(8), 1913\u20131924 (2019)","journal-title":"Cancer Res."},{"key":"1282_CR59","doi-asserted-by":"publisher","first-page":"217232","DOI":"10.1016\/j.canlet.2024.217232","volume":"604","author":"X Liu","year":"2024","unstructured":"X. Liu, Z. Ma, X. Jing, G. Wang, L. Zhao, X. Zhao, Y. Zhang, The deubiquitinase OTUD5 stabilizes SLC7A11 to promote progression and reduce paclitaxel sensitivity in triple-negative breast cancer. Cancer Lett. 604, 217232 (2024)","journal-title":"Cancer Lett."},{"issue":"45","key":"1282_CR60","doi-asserted-by":"publisher","first-page":"e2403995","DOI":"10.1002\/advs.202403995","volume":"11","author":"J Liu","year":"2024","unstructured":"J. Liu, Y. Luo, S. Chen, G. Wang, W. Jin, W. Jiang, M. Li, Y. Wang, J. Yu, H. Wei et al., Deubiquitylase USP52 Promotes Bladder Cancer Progression by Modulating Ferroptosis through Stabilizing SLC7A11\/xCT. Adv. Sci. (Weinh). 11(45), e2403995 (2024)","journal-title":"Adv. Sci. (Weinh)"},{"issue":"5","key":"1282_CR61","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.7150\/thno.48112","volume":"11","author":"C Zhang","year":"2021","unstructured":"C. Zhang, X. Wang, D. Fang, P. Xu, X. Mo, C. Hu, A. Abdelatty, M. Wang, H. Xu, Q. Sun et al., STK39 is a novel kinase contributing to the progression of hepatocellular carcinoma by the PLK1\/ERK signaling pathway. Theranostics. 11(5), 2108\u20132122 (2021)","journal-title":"Theranostics"},{"issue":"1","key":"1282_CR62","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s13046-025-03531-3","volume":"44","author":"J Liu","year":"2025","unstructured":"J. Liu, J. Jiang, J. Huang, Z.E. Fang, L. Liu, Y. Liu, W. Nian, J. Tang, Z. Wang, Bufalin inhibits hepatocellular carcinoma progression by blocking EGFR-mediated RAS-RAF-MEK-ERK pathway activation. J. Exp. Clin. Cancer Res. 44(1), 260 (2025)","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"2","key":"1282_CR63","doi-asserted-by":"publisher","first-page":"637","DOI":"10.7150\/ijbs.66915","volume":"18","author":"YM Liu","year":"2022","unstructured":"Y.M. Liu, Y. Cao, P.S. Zhao, L.Y. Wu, Y.M. Lu, Y.L. Wang, J.F. Zhao, X.G. Liu, CircCCNB1 silencing acting as a miR-106b-5p sponge inhibited GPM6A expression to promote HCC progression by enhancing DYNC1I1 expression and activating the AKT\/ERK signaling pathway. Int. J. Biol. Sci. 18(2), 637\u2013651 (2022)","journal-title":"Int. J. Biol. Sci."},{"issue":"9","key":"1282_CR64","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1158\/0008-5472.CAN-17-2432","volume":"78","author":"Y Liu","year":"2018","unstructured":"Y. Liu, X. Zhang, B. Yang, H. Zhuang, H. Guo, W. Wei, Y. Li, R. Chen, Y. Li, N. Zhang, Demethylation-Induced Overexpression of Shc3 Drives c-Raf-Independent Activation of MEK\/ERK in HCC. Cancer Res. 78(9), 2219\u20132232 (2018)","journal-title":"Cancer Res."},{"issue":"1","key":"1282_CR65","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1186\/s12951-024-02827-4","volume":"22","author":"Y Wu","year":"2024","unstructured":"Y. Wu, H. Bao, J. Wu, B. Chen, J. Xu, K. Jin, L. Chen, G. Zhu, F. Wang, ACYP2 functions as an innovative nano-therapeutic target to impede the progression of hepatocellular carcinoma by inhibiting the activity of TERT and the KCNN4\/ERK pathway. J. Nanobiotechnol. 22(1), 557 (2024)","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"1282_CR66","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13046-025-03386-8","volume":"44","author":"B Zhao","year":"2025","unstructured":"B. Zhao, Y. Zhou, N. Cheng, X. Zheng, G. Chen, X. Qi, X. Zhang, F. Wang, Q. Zhuang, Y.G. Assaraf et al., Targeted inhibition of PDGFRA with avapritinib, markedly enhances lenvatinib efficacy in hepatocellular carcinoma in vitro and in vivo: clinical implications. J. Exp. Clin. Cancer Res. 44(1), 139 (2025)","journal-title":"J. Exp. Clin. Cancer Res."}],"container-title":["Cellular Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13402-026-01282-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-026-01282-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-026-01282-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:20:50Z","timestamp":1790324450000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13402-026-01282-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":66,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["1282"],"URL":"https:\/\/doi.org\/10.1007\/s13402-026-01282-7","relation":{},"ISSN":["2211-3436"],"issn-type":[{"value":"2211-3436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"17 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All participants in this study signed informed consent. All procedures involving human participants were in accordance with the ethical standards of the Research Ethics Committee of The First Affiliated Hospital of Xian Jiaotong University. All animal experiments were approved by the Biomedical Ethics Committee of Health Science Center of Xi\u2019an Jiaotong University.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"123"}}